Curriculum Vitae

May 01, 2022

Steffen Ventz, PhD
Department of Data Sciences,
Dana-Farber Cancer Institute and
Department of Biostatistics,
Harvard T.H. Chan School of Public Health

450 Brookline Avenue, CLSB11032,
Boston, MA, 02215,
Email: steffen.ventz.81@gmail.com
Tel: (617) 259-8412
Web: https://steffen-ventz.github.io

EDUCATION

2005	Vordiplom (equivalent to BS)	Demography	University of Rostock, Rostock, Germany
2007	Diplom (equivalent to MS)	Demography	University of Rostock, Rostock, Germany
2010	MPhil	Statistics	Bocconi University, Milan, Italy
2013	PhD	Statistics	Bocconi University, Milan, Italy

POSTDOCTORAL TRAINING

02/2013 – 09/2015 Department of Biostatistics, Harvard T.H. Chan School of Public Health Boston, MA

ACADEMIC APPOINTMENTS

02/2013 – 09/2015 Research Fellow, Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA

09/2015 – 07/2018 Assistant Professor of Statistics, Department of Computer Science and Statistics, University of Rhode Island, Kingston, RI

08/2018 – present Research Scientist (equivalent to Research Assistant Professor), Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA

OTHER POSITIONS

02/2006 – 04/2006 Research Internship, Max-Planck Institute for Demographic Research, Rostock, Germany.

08/2006 – 07/2007 Research Assistant, Max-Planck Institute for Demographic Research, Rostock, Germany.

01/2007 – 07/2007 Research Assistant, Rostock Center for Demography, Rostock, Germany.

09/2007 – 07/2008 Max-Planck EDSD Fellow, Institute National D'Etudes Demographiques, Paris, France.

09/2012 – 01/2013 Visiting Scientist, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute.

RESEARCH INTERESTS

Bayesian Statistics, Sequential Statistics, Statistical Decision Theory, Causal Inference, Graphical Models, Adaptive Design of Experiments, Basket/Platform Designs, Multi-Study Prediction Models, Meta-Analysis, Data-Integration

INVITED PRESENTATIONS

06/2011	Invited Talk	8th Workshop on Bayesian Nonparametrics, Veracruz, Mexico
02/2014	Invited Talk	Algorithm for Threat Detection Workshop, Boulder, CO
01/2015	Seminar	School of Health Sciences, University of Nevada, Reno, NV
02/2015	Seminar	Department of Computer Science and Statistics, University of Rhode Island, Kingston, RI
02/2015	Seminar	Department of Mathematics, New College of Florida, Sarasota, FL
03/2015	Seminar	Quantitative Issues in Cancer Research, Harvard University, Boston, MA
03/2015	Seminar	Department of Biostatistics, University of Rochester, Rochester, NY
03/2015	Seminar	Department of Mathematics, Tennessee Technical University, Cookeville, TN
03/2015	Seminar	Department of Epidemiology, New York Medical College, Valhalla, NY
03/2015	Seminar	School of Public Health, City University of New York, New York, NY
04/2016	Invited Talk	New England Statistics Symposium, Yale University, New Haven, CT
06/2016	Invited Talk	ISBA World Meeting, Santa Margarita, Italy
06/2016	Seminar	University deli Studi di Milano, Milan, Italy
03/2017	Seminar	BCB How It's Done Series, Dana-Farber Cancer Institute, Boston, MA
5/2017	Invited Talk	Midwest Biopharmaceutical Statistics Workshop, Muncie, IN
08/2017	Seminar	International Breast Cancer Study Group, Boston, MA
11/2017	Seminar	Department of Epidemiology and Biostatistics, McGill University, Montreal, Canada

11/2017	Seminar	Department of Mathematics, Bentley University, Waltham, MA
02/2017	Seminar	Department of Population Health, New York University, New York, NY
01/2018	Seminar	Department of Statistics, Florida State University, Tallahassee, FL
01/2018	Seminar	Department of Biostatistics, University of Florida, Gainesville, FL
02/2018	Seminar	Department of Biostatistics, Yale University, New Haven, CT
02/2020	Workshop	Department of Biostatistics, Monash University, Melbourne, Australia
03/2020	Workshop	NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia
08/2020	Seminar	Data-Analytics Division, Project Data Sphere, Cary, NC
11/2020	Invited Talk	Society for Neuro-Oncology Annual Meeting, Virtual Meeting, SNO
11/2020	Seminar	Department of Mathematics, University of Bath, Bath, UK
12/2020	Seminar	Department of Mathematics, Aarhus University, Aarhus, Denmark
03/2021	Seminar	School of Mathematics and Statistics, University of Glasgow, Glasgow, UK
03/2021	Seminar	Department of Mathematical Sciences, Durham University, Durham, UK
03/2021	Seminar	Department of Mathematics and Statistics, San Diego State University, San Diego, CA
05/2021	Seminar	Biostatistics Center, Division of Clinical Research, Massachusetts General Hospital, Boston, MA
06/2021	Seminar	Division of Biostatistics, Department of Public Health Sciences, UC Davis, Davis, CA
12/2021	Seminar	Department of Epidemiology and Biostatistics, University of South Carolina, Columbia, SC
01/2022	Seminar	Division of Biostatistics, University of Minnesota, Minneapolis, MN
02/2022	Seminar	Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA
02/2022	Seminar	Department of Biostatistics, University of Florida, Gainesville, FL
02/2022	Seminar	Department of Biostatistics, University of Texas MD Anderson Cancer Center, Houston, TX
03/2022	Seminar	Department of Statistics, University of Nebraska, Lincoln, NE
03/2022	Seminar	Department of Mathematics and Statistics, University of North Carolina, Charlotte, NC

CONTRIBUTED PRESENTATIONS

05/2008	Contributed Talk	Stanford Workshop in Formal Demography, Palo Alto, CA
10/2010	Contributed Talk	Young European Statisticians Workshop, Eindhoven, NL
06/2011	Poster	8th Workshop on Bayesian Nonparametrics, Veracruz, Mexico

PEER-REVIEWED PUBLICATIONS

1. **Steffen Ventz** and Lorenzo Trippa. Bayesian designs and the control of frequentist characteristics: a practical solution. *Biometrics*, 71(1):218–226, 2015. doi:10.1111/biom.12226

2. Elodie Hatchi, Konstantina Skourti-Stathaki, **Steffen Ventz**, Luca Pinello, Angela Yen, Kinga Kamieniarz-Gdula, Stoil Dimitrov, Shailja Pathania, Kristine M. McKinney, Matthew L. Eaton, et al. BRCA1 recruitment to transcriptional pause sites is required for r-loop-driven DNA damage repair. *Molecular Cell*, 57(4):636–647, 2015. doi:10.1016/j.molcel.2015.01.011

3. Matteo Cellamare, Melisa Milstein, **Steffen Ventz**, Elisa Baudin, Lorenzo Trippa, and Carol D. Mitnick. Bayesian adaptive randomization in a clinical trial to identify new regimens for MDR-TB: the endTB trial. *The International Journal of Tuberculosis and Lung Disease*, 20(12):S8–S12, 2016. doi:10.5588/ijtld.16.0066

4. Matteo Cellamare*, **Steffen Ventz* (Co-first author)**, Elisa Baudin, Carol D. Mitnick, and Lorenzo Trippa. A Bayesian response-adaptive trial in tuberculosis: The endTB trial. *Clinical Trials*, 14(1):17–28, 2017. doi:10.1177/1740774516665090

5. **Steffen Ventz**, Giovanni Parmigiani, and Lorenzo Trippa. Combining Bayesian experimental designs and frequentist data analyses: motivations and examples. *Applied Stochastic Models in Business and Industry*, 33(3):302–313, 2017. doi:10.1002/asmb.2249

6. **Steffen Ventz**, William T. Barry, Giovanni Parmigiani, and Lorenzo Trippa. Bayesian response-adaptive designs for basket trials. *Biometrics*, 73(3):905–915, 2017. doi:10.1111/biom.12668

7. **Steffen Ventz**, Brian M. Alexander, Giovanni Parmigiani, Richard D. Gelber, and Lorenzo Trippa. Designing clinical trials that accept new arms: An example in metastatic breast cancer. *Journal of Clinical Oncology*, 35(27):3160–3168, 2017. doi:10.1200/JCO.2016.70.1169

8. Emma Schwager, Himel Mallick, **Steffen Ventz**, and Curtis Huttenhower. A Bayesian method for detecting pairwise associations in compositional data. *PLoS Computational Biology*, 13(11):e1005852, 2017. doi:10.1371/journal.pcbi.1005852

9. Alyssa M. Vanderbeek, Rifaquat Rahman, Geoffrey Fell, **Steffen Ventz**, Tianqi Chen, Robert Redd, Giovanni Parmigiani, Timothy F. Cloughesy, Patrick Y.

Wen, Lorenzo Trippa, and Brian M. Alexander. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? *Neuro-Oncology*, 20(8):1034–1043, 2018. doi:10.1093/neuonc/noy027

10. **Steffen Ventz**, Matteo Cellamare, Giovanni Parmigiani, and Lorenzo Trippa. Adding experimental arms to platform clinical trials: randomization procedures and interim analyses. *Biostatistics*, 19(2):199–215, 2018. doi:10.1093/biostatistics/kxx030

11. **Steffen Ventz**, Brian M. Alexander, and Lorenzo Trippa. Bayesian adaptive randomization in dose-finding trials. *Journal of the American Medical Association - Network*, 1(8):e186075, 2018. doi:10.1001/jamanetworkopen.2018.6075

12. Rifaquat Rahman*, **Steffen Ventz* (Co-first author)**, Geoffrey Fell, Alyssa M. Vanderbeek, Lorenzo Trippa, and Brian M. Alexander. Divining responder populations from survival data. *Annals of Oncology*, 30(6):1005–1013, 2019. doi:10.1093/annonc/mdz087

13. Alyssa M. Vanderbeek*, **Steffen Ventz* (Co-first author)**, Rifaquat Rahman, Geoffrey Fell, Lorenzo Trippa, and Brian M. Alexander. To randomize, or not to randomize, that is the question: a meta-analytic methodology for determining the context-specific value of randomization. *Neuro-Oncology*, 21(10):1239–1249, 2019. doi:10.1093/neuonc/noz097

14. Rifaquat Rahman, Geoffrey Fell, **Steffen Ventz**, Andrea Arfe, Alyssa M. Vanderbeek, Lorenzo Trippa, and Brian M. Alexander. Deviation from the proportional hazards assumption in randomized phase III clinical trials in oncology: Prevalence, associated factors and implications. *Clinical Cancer Research*, 25(21):6339–6345, 2019. doi:10.1158/1078-0432.CCR-18-3999

15. **Steffen Ventz**, Matteo Cellamare, Sergio Bacallado, and Lorenzo Trippa. Bayesian uncertainty directed trial designs. *Journal of the American Statistical Association*, 114(527):962–974, 2019. doi:10.1080/01621459.2018.1497497

16. **Steffen Ventz**, Albert Lai, Timothy F. Cloughesy, Patrick Y. Wen, Lorenzo Trippa, and Brian M. Alexander. Design and evaluation of an external control arm using prior clinical trials and real-world data. *Clinical Cancer Research*, 25(16):4993–5001, 2019. doi:10.1158/1078-0432.CCR-19-0820

17. **Steffen Ventz**, Lorenzo Trippa, and Jonathan Schoenfeld. Lessons learned from de-escalation trials in favorable risk HPV-associated squamous cell head and neck cancer – a perspective on future trial designs. *Clinical Cancer Research*, 25(24):7281–7286, 2019. doi:10.1158/1078-0432.CCR-19-0945

18. **Steffen Ventz***, Ilaria Dominicano***(Co-first author)**, Matteo Cellamare, Raymond H. Mak, and Lorenzo Trippa. Bayesian uncertainty-directed dose-finding designs. *Journal of the Royal Statistical Society - C*, 68(5):1393–1410, 2019. doi:10.1111/rssc.12355

19. Andrea Arfe, **Steffen Ventz**, and Lorenzo Trippa. Shared and usable data from phase I oncology trials: an unmet need. *Journal of the American Medical Association - Oncology*, 6(7):980–981, 2020. doi:10.1001/jamaoncol.2020.0144

20. Shervin Tabrizi, Lorenzo Trippa, Daniel Cagney, Shyam Tanguturi, **Steffen Ventz**, Geoffrey Fell, Patrick Y. Wen, Brian M. Alexander, and Rifaquat Rahman. A quantitative framework for modeling covid-19 risk during adjuvant therapy using published randomized trials of glioblastoma in the elderly. *Neuro-Oncology*, 22(7):918–927, 2020. doi:10.1093/neuonc/noaa111

21. Nadine Tung, Mark E. Robson, **Steffen Ventz**, Cesar Santa-Maria, Rita Nanda, Paul Kelly Marcom, Payal D. Shah, Tarah J. Ballinger, Eddy Yang, Shaveta Vinayak, Michelle Melisko, Adam Brufsky, Michelle DeMeo, Colby Jenkins, Susan Domchek, Alan D'Andrea, Nancy Lin, Melissa Hughes, Nick Wagle, Gerburg Wulf, Ian E. Krop, Antonio C. Wolff, Eric P. Winer, and Judy E. Garber. Tbcrc 048: A phase ii study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in homologous recombination (hr)-pathway genes (olaparib expanded). *Journal of Clinical Oncology*, 38(36):4274–4282, 2020. doi:10.1200/JCO.20.02151

22. Nadine Tung, Mark E. Robson, **Steffen Ventz**, Cesar Santa-Maria, Rita Nanda, Paul Kelly Marcom, Payal D. Shah, Tarah J. Ballinger, Eddy Yang, Shaveta Vinayak, Michelle Melisko, Adam Brufsky, Michelle DeMeo, Colby Jenkins, Susan Domchek, Alan D'Andrea, Nancy Lin, Melissa Hughes, Nick Wagle, Gerburg Wulf, Ian E. Krop, Antonio C. Wolff, Eric P. Winer, and Judy E. Garber. Tbcrc 048: A phase ii study of olaparib monotherapy in metastatic breast cancer patients with germline or somatic mutations in dna damage response (ddr) pathway genes (olaparib expanded). *Journal of Clinical Oncology*, 38(15S):1002–1002, 2020. doi:0.1200/JCO.2020.38.15_suppl.1002

23. Shervin Tabrizi, Lorenzo Trippa, Daniel Cagney, Ayal A. Aizer, Shyam Tanguturi, **Steffen Ventz**, Geoffrey Fell, Jennifer R. Bellon, Harvey Mamon, Paul L. Nguyen, Anthony V. D'Amico, Daphne Haas-Kogan, Brian M. Alexander, and Rifaquat Rahman. Interpreting randomized trials in oncology with incorporation of covid-19 risk associated with cancer therapy. *Journal of the American Medical Association - Network*, 3(4):e213304, 2021. doi:10.1001/jamanetworkopen.2021.3304

24. Geoffrey Fell, Robert Redd, Alyssa M. Vanderbeek, Rifaquat Rahman, Andrea Arfè, Brian M. Alexander, **Steffen Ventz * (Co-last author)**, and Lorenzo Trippa*. Kmdata: A curated database of recapitulated individual patient level data from 160 oncology clinical trials published between 2014 and 2016. *DATABASE (in press)*, 2021. doi:10.1093/database/baab037

25. Rifaquat Rahman, **Steffen Ventz**, Jon McDunn, Bill Louv, Irmarie Reyes-Rivera, Mei-Yin Chen Polley, Fahar Merchant, Lauren E. Abrey, Joshua Allen, Laura K. Aguilar, Estuardo Aguilar Cordova, David Arons, Kirk Tanner, Stephen Bagley, Mustafa Khasraw, Timothy Cloughesy, Patrick Y. Wen, Brian M. Alexander, and Lorenzo Trippa. Leveraging external data for externally controlled trial designs in oncology. *The Lancet Oncology*, 2021. doi:10.1016/S1470-2045(21)00488-5

26. Massimiliano Russo, **Steffen Ventz**, Victoria Wang, and Lorenzo Trippa. Inference in response-adaptive clinical trials when the enrolled population varies over time. *Biometrics (in press)*, 2022. doi:10.1111/biom.13582

27. **Steffen Ventz**, Sergio Bacallado, Rifaquat Rahman, Sara Tolaney, Jonathan Schoenfeld, Brian M. Alexander, and Lorenzo Trippa. Informed patients, better trials? Opportunities and pitfalls in communicating early evidence. *Nature Communications*, 12(801):1–7, 2021. doi:10.1038/s41467-021-21116-4

28. **Steffen Ventz**, Leah Comment, Bill Louv, Patrick Y. Wen, Brian M. Alexander, and Lorenzo Trippa. The use of external control data for predictions and interim analyses in clinical studies. *Neuro-Oncology*, 24(2):247–256, 2022. doi:10.1093/neuonc/noab141

29. **Steffen Ventz**, Rahul Mazumder, and Lorenzo Trippa. Integration of survival data from multiple studies. *Biometrics (in press)*, 2022. doi:10.1111/biom.13517

30. Marta Bonsaglio, Sandra Fortini, **Steffen Ventz**, and Lorenzo Trippa. Approximating operating characteristics of bayesian uncertainty directed trial designs. *Journal of Statistical Planning and Inference (in press)*, 2022. doi:https://doi.org/10.1016/j.jspi.2022.03.001

SUBMITTED MANUSCRIPTS AND INVITED REVISIONS

30. **Steffen Ventz** and Lorenzo Trippa. Bayesian multi-arm de-intensification designs. *Bayesian Analysis (invited resubmission)*, 2022

31. **Steffen Ventz**, Sean Khozin, Bill Louv, Jacob Sands, Rifaquat Rahman, Leah Comment, Lorenzo Trippa, and Brian M. Alexander. Design and evaluation of hybrid controlled trials leveraging external data and randomization. *Nature communications (minor resubmission)*, 2022

32. Julie C. Lauffenburger, Niteesh K. Choudhry, Massimiliano Russo, Robert J. Glynn, **Steffen Ventz**, and Lorenzo Trippa. Leveraging adaptive randomized trials for the evaluation of interventions in health services and implementation research: potential advantages and practical considerations. *BMJ Medicine (minor revision)*, 2022

FUNDING

Current

- Title: Olaparib Monotherapy in Metastatic Breast Cancer Patients with PALB2 and sBRCA1/or sBRCA2 Mutations (Olaparib Expanded 2).
  Sponsor: AstraZeneca,
  PI: N. Tung, Beth Israel Deaconess Medical Center,
  Project period: 05/2020-11/2022,
  Role: Statistician.

- Title: Nano-SMART - An adaptive phase I–II trial of AGuIX gadolinium-based nanoparticles with stereotactic magnetic resonance-guided adaptive radiation therapy in centrally located non-small cell lung cancer and locally advanced unresectable pancreatic ductal adenocarcinoma.
  Sponsor: NIH Theraguix,
  PI: D. Cagney, Dana-Farber Cancer Institute,
  Project period: 09/2020–09/2025,
  Role: Statistician.

- Title: External Control Arm Development for Cancer Research.
  Sponsor: Project Data Sphere, LLC
  Project period: 09/2019-06/2022,
  Role: Investigator.

- NIH RO1,
  Title: Statistical Methods and Validation Analyses for the Integration of External Data.
  PI: L Trippa, Dana-Farber Cancer Institute,
  Project period: 9/1/2020-8/31/25,
  Role: Investigator.

Pending

- NIH UG3,
  Title: Adaptive de-escalation of treatment for HPV associated oropharyngeal cancer.
  PI: J. Schoenfeld, Dana-Farber Cancer Institute,
  Project period: 11/2022-11/2026,
  Role: Statistician.

Previous

- Title: BrTK-03: A two-stage hybrid trial design for radiation in combination with Temozolomide vs GMCI.
  Sponsor: Advantagene Inc,
  PI: L.Trippa, Dana-Farber Cancer Institute,
  Project period: 11/2019-10/2020,
  Role: Statistician.

- Title: A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded).
  Sponsor: AstraZeneca,
  PI: N. Tung, Beth Israel Deaconess Medical Center,
  Project period: 10/2019-09/2021,
  Role: Statistician.

- Wong Family Award,
  Title: Designing Clinical Studies of Targeted Drugs Across Cancer Modalities,
  PI: W. Barry, Dana-Farber Cancer Institute,
  Project period: 2014 – 2015,
  Role: Statistician.

- NSF DMS-1042785,
  Title: ATD - Quantitative Methods for Estimating Sequencing Errors,
  PI: G. Parmigiani, Dana-Farber Cancer Institute,
  Project period: 2012 – 2015,
  Role: Statistician.

- Title: Leveraging Real World Evidence to Evaluate for a Trial Effect and to Develop Externally Controlled Trials for Glioblastoma
  Sponsor: JCRT Foundation, Inc.
  PI: R. Rahman, Dana-Farber Cancer Institute
  Project period: 5/2020-6/2021,
  Role: Statistician.

PROFESSIONAL SERVICES

National Level

2018 – 2019 FDA/Project-Datasphere Task-forced on External Control Arms for Small Cell Lung Cancer.

2018 ISBA World Meeting, 2018, Organizer of the session: "Bayesian clinical trial designs for precision medicine"

2020 ISBA World Meeting, 2020, Organizer of the session: "Adaptive Bayesian Designs for Early Stage Clinical studies"

University of Rhode Island

2015 – 2016 Data Science Hiring Committee - Assistant Professor of Statistics.

2015 – 2016 Data Science Hiring Committee - Assistant Professor of Electrical Engineering.

2015 – 2016 Data Science Hiring Committee - Assistant Professor of Biology.

2015 – 2016 Statistics Administrative Committee.

2015 – 2016 Machine Learning and Computational Statistics Graduate Curriculum Committee.

2015 – 2016 Data Science Undergraduate B.S. Curriculum Committee.

2016 – 2017 Statistics Administrative Committee.

2016 – 2017 Hiring Committee - Assistant Professor of Statistics.

2016 – 2017 Hiring Committee - Lecturer in Statistics.

2016 – 2017 Machine Learning and Computational Statistics Graduate Curriculum Committee.

2016 – 2017 Data Science Undergraduate B.A. and B.S. Curriculum Committee.

2017 – 2018 Undergraduate Statistics B.S. and B.A. Committee and Co-director.

2017 – 2018 Statistics Administrative Committee.

2017 – 2018 Data Science Graduate MS Curriculum Committee.

2017 – 2018 Machine Learning and Computational Statistics Graduate Curriculum Committee.

2017 – 2018 Department of Computer Science and Statistics Self-Evaluation Committee.

Examination Committees

10/2016 Davin Amin, M.S. Statistics Examination, Department of Computer Science and Statistics, University of Rhode Island.

11/2016 Zack Babcock, PhD Examination, College of Pharmacy, University of Rhode Island.

06/2017 Anton Lobach, M.S. Statistics Examination, Department of Computer Science and Statistics, University of Rhode Island.

11/2017 Leandro Moreira da Costa, PhD CS Examination, Department of Computer Science and Statistics, University of Rhode Island.

04/2018 Andrew Tucker, M.S. Electrical Engineering Examination, School of Engineering, University of Rhode Island.

04/2018 Katie Duo, M.S. Statistics Examination, Department of Computer Science and Statistics, University of Rhode Island.

04/2018 Caoxin Sun, M.S. Statistics Examination, Department of Computer Science and Statistics, University of Rhode Island.

TEACHING EXPERIENCE

Bocconi University

09/2017 – 12/2017	Teaching Assistant		Probability and Stochastic Calculus

University of Rhode Island

09/2015 – 12/2015	Instructor	STA 592(1)	Introduction to Survival and Event-History Analysis*
01/2016 – 05/2016	Instructor	STA 492(1)	Computational Statistics*
01/2016 – 05/2016	Instructor	STA 307	Introduction to Biostatistics
09/2016 – 12/2016	Instructor	STA 592(2)	Semi- and Nonparametric Statistics*
09/2016 – 12/2016	Instructor	STA 492(2)	Bayesian Statistics*
01/2017 – 05/2017	Instructor	STA 307	Introduction to Biostatistics
01/2017 – 05/2017	Instructor	STA 542	Categorical Data-Analysis*
09/2017 – 12/2017	Instructor	STA 305	Statistics with R*
09/2017 – 12/2017	Instructor	STA 592(1)	Introduction to Survival and Event-History Analysis
01/2018 – 05/2018	Instructor	STA 542	Categorical Data-Analysis
01/2018 – 05/2018	Instructor	STA 307(1)	Introduction to Biostatistics-1
01/2018 – 05/2018	Instructor	STA 307(2)	Introduction to Biostatistics-2

*** = new course, created by Instructor**

ADVISING

PhD Students

2013 – 2015 Matteo Cellamare, PhD in statistics, Sapienza University of Rome.

2015 – 2018 Ilaria Domenicano, PhD in statistics, Sapienza University of Rome.

2015 – 2018 Emma Schwager, PhD in biostatistics, Harvard T.H. Chan School of Public Health.

2018 – present Gopal Kotecha, PhD in biostatistics, Harvard T.H. Chan School of Public Health.

Master Students

2015 – 2016 Davin Amin, M.S. in statistics, University of Rhode Island.

2017 – 2018 Divana Boukari, M.S. in statistics, University of Rhode Island.

2017 – 2018 Hai-Shuo Shu, M.S. in statistics, University of Rhode Island.

2017 – 2018 John Ragland, M.S. in statistics, University of Rhode Island.